Compare AbCellera Biologics Inc (ABCL) vs Citigroup Inc. (C) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Citigroup Inc. — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Citigroup Inc. trades at $137.86 (market cap $240.09B). The key difference: Citigroup Inc. is far larger — about 102.2× AbCellera Biologics Inc's market cap, and Citigroup Inc. pays a 1.7% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | C | |
|---|---|---|
Market Cap | $2.35B | $240.09B |
Sector | Health | Financials |
52-Week High | $8.12 | $145.67 |
52-Week Low | $2.78 | $85.57 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Citigroup (C) trades at $140.75, up 0.59% today, with a bullish technical outlook and strong analyst support. Recent Q1 2026 earnings beat expectations, and the company expanded its services by joining LPMCL. Revenue and net income have grown steadily, with a P/E of 17.78 and a consensus price target of $151.36. The stock is near its 52-week high, reflecting positive momentum.
The outlook is positive, driven by earnings growth and strategic expansions, but risks include volatile cash flows and high debt levels. Wall Street sentiment is bullish, with 59% of analysts rating it a buy. Investors should weigh the strong fundamentals against macroeconomic and operational risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
